Spironolactone revisited.
作者信息
Polyzos Stergios A, Kountouras Jannis, Zavos Christos, Deretzi Georgia
出版信息
J Clin Hypertens (Greenwich). 2011 Oct;13(10):783-4. doi: 10.1111/j.1751-7176.2011.00484.x. Epub 2011 Jul 18.
Abstract
摘要
相似文献
1
Spironolactone revisited.螺内酯再探讨。
J Clin Hypertens (Greenwich). 2011 Oct;13(10):783-4. doi: 10.1111/j.1751-7176.2011.00484.x. Epub 2011 Jul 18.
2
Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome.醛固酮拮抗剂可降低代谢综合征肥胖患者的血压并改善代谢参数。
J Clin Hypertens (Greenwich). 2010 Sep;12(9):753-5. doi: 10.1111/j.1751-7176.2010.00339.x. Epub 2010 Jul 8.
3
[Spironolactone reduces blood pressure and albuminuria of obese hypertensive patients with metabolic syndrome].[螺内酯可降低肥胖型高血压合并代谢综合征患者的血压及蛋白尿]
J Bras Nefrol. 2013 Jan-Mar;35(1):69-72. doi: 10.5935/01012800.20130011.
4
Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.依普利酮：一种用于治疗高血压和心力衰竭的选择性醛固酮受体拮抗剂。
Heart Dis. 2003 Sep-Oct;5(5):354-63. doi: 10.1097/01.hdx.0000089783.30450.cb.
5
False claims of blood pressure-independent protection by blockade of the renin angiotensin aldosterone system?通过阻断肾素-血管紧张素-醛固酮系统实现与血压无关的保护作用，这一说法是否存在虚假？
Hypertension. 2003 Feb;41(2):193-6. doi: 10.1161/01.hyp.0000049882.23078.eb.
6
Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.螺内酯、依普利酮和新型醛固酮受体拮抗剂在内分泌性和原发性高血压中的应用。
J Hypertens. 2013 Jan;31(1):3-15. doi: 10.1097/HJH.0b013e3283599b6a.
7
Spontaneous, L-arginine-induced and spironolactone-induced regression of protein remodeling of the left ventricle in L-NAME-induced hypertension.在L-NAME诱导的高血压中，自发性、L-精氨酸诱导和螺内酯诱导的左心室蛋白质重塑消退。
Physiol Res. 2007;56 Suppl 2:S55-S62. doi: 10.33549/physiolres.931398. Epub 2007 Sep 5.
8
Long-term use of low-dose spironolactone in spontaneously hypertensive rats: effects on left ventricular hypertrophy and stiffness.长期使用低剂量螺内酯治疗自发性高血压大鼠：对左心室肥厚和僵硬度的影响。
Pharmacol Rep. 2011;63(4):975-82. doi: 10.1016/s1734-1140(11)70613-2.
9
Spironolactone differently influences remodeling of the left ventricle and aorta in L-NAME-induced hypertension.螺内酯对L-NAME诱导的高血压模型中左心室和主动脉重塑的影响不同。
Physiol Res. 2007;56 Suppl 2:S25-S32. doi: 10.33549/physiolres.931394. Epub 2007 Sep 5.
10
Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.螺内酯对少尿-无尿血液透析患者血压及肾素-血管紧张素-醛固酮系统的影响
Am J Kidney Dis. 2005 Jul;46(1):94-101. doi: 10.1053/j.ajkd.2005.03.005.
引用本文的文献
1
Update on the Complications and Management of Liver Cirrhosis.肝硬化并发症与管理的最新进展
Med Sci (Basel). 2025 Feb 5;13(1):13. doi: 10.3390/medsci13010013.
本文引用的文献
1
Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease.螺内酯和维生素 E 对非酒精性脂肪性肝病患者血清代谢参数及胰岛素抵抗的影响。
J Renin Angiotensin Aldosterone Syst. 2011 Dec;12(4):498-503. doi: 10.1177/1470320311402110. Epub 2011 Mar 24.
2
Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome.螺内酯治疗对非肥胖多囊卵巢综合征女性内皮功能的影响。
Eur J Endocrinol. 2011 Mar;164(3):389-95. doi: 10.1530/EJE-10-0709. Epub 2010 Dec 13.
3
Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome.醛固酮拮抗剂可降低代谢综合征肥胖患者的血压并改善代谢参数。
J Clin Hypertens (Greenwich). 2010 Sep;12(9):753-5. doi: 10.1111/j.1751-7176.2010.00339.x. Epub 2010 Jul 8.
4
Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet.螺内酯通过改善肝脂肪变性和炎症，抑制高脂肪高果糖饮食诱导的糖异生，改善糖和脂代谢。
Endocrinology. 2010 May;151(5):2040-9. doi: 10.1210/en.2009-0869. Epub 2010 Mar 8.
5
Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker.比较小剂量螺内酯与噻嗪类利尿剂在血管紧张素转换酶抑制剂或血管紧张素Ⅱ受体拮抗剂治疗的高血压患者中的疗效。
Clin Exp Hypertens. 2009 Nov;31(8):648-56. doi: 10.3109/10641960903407017.
6
Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage.
Clin Nephrol. 2009 Dec;72(6):449-56. doi: 10.5414/cnp72449.
7
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.在糖尿病肾病中，于最大程度的血管紧张素转换酶抑制基础上加用血管紧张素受体阻滞剂或盐皮质激素拮抗剂。
J Am Soc Nephrol. 2009 Dec;20(12):2641-50. doi: 10.1681/ASN.2009070737. Epub 2009 Nov 19.
8
Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism.螺内酯对血脂谱的短期影响：对一组患有多毛症的年轻女性进行的为期 3 个月的研究。
Br J Clin Pharmacol. 2009 Oct;68(4):634-7. doi: 10.1111/j.1365-2125.2009.03483.x.
9
Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?心力衰竭和肝硬化中的钠潴留：盐皮质激素拮抗剂利钠剂量的潜在作用？
Circ Heart Fail. 2009 Jul;2(4):370-6. doi: 10.1161/CIRCHEARTFAILURE.108.821199.
10
Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines.非酒精性脂肪性肝病：胰岛素抵抗和脂肪细胞因子的致病作用
Curr Mol Med. 2009 Apr;9(3):299-314. doi: 10.2174/156652409787847191.
Zotero 插件